Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2016 by Mayo Clinic
Sponsor:
Collaborators:
National Cancer Institute (NCI)
FDA Office of Orphan Products Development
Information provided by (Responsible Party):
Mayo Clinic
ClinicalTrials.gov Identifier:
NCT01003769
First received: October 28, 2009
Last updated: April 19, 2016
Last verified: April 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: March 2018 (Final data collection date for primary outcome measure)